Strong revenue growth, accelerated investments and initial promising results for iBiopsy. Revenue surges 47.9% compared with the first half of 2019 at €5.9m. Order backlog up 40% over six months to €53.6m. Cash and cash equivalents of €19.4m as of June 30, 2020
Read moreMedian Technologies today announced the promising results of a first retrospective study on the implementation of the iBiopsy® platform for the analysis of patients with solid tumor cancer who are likely to be responsive to immuno-oncology treatments such as those based on immune checkpoint inhibitors (ICIs)
Read moreFirst-half revenue up 47.9% to €5.9 million, compared with €4.0 million in H1 2019 – 7 consecutive quarters of revenue growth – Order backlog to €53.6 million as of June 30th, 2020, up 40% compared with order backlog as of December 31st, 2019 and up 74.6% compared with order backlog as of June 30th, 2019 – Cash and cash equivalents expected to reach €19.4 million
Read moreMedian Technologies announced today that it has been awarded the Euronext European Rising Tech Label. The European Rising Tech Label recognizes 98 top-performing companies among more than 350 small and mid-caps listed on Euronext markets in Amsterdam, Brussels, Dublin, Lisbon and Paris, in the Tech sector (i.e., Life Sciences, Clean Tech and Technology, Media & Telecom).
Read moreTo download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]